As discussed above, the numbers of CD4‐stimulated cDC2s and CD8‐stimulated cDC1s, including resident cDC1s and migratory cDC1s, were significantly increased in tumor and peripheral blood, which suggests that DCs were activated after NE(PD1nb) treatment. This evidence concerns the gene CD8A and neoplasm.